Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:DBVT NASDAQ:HOWL NASDAQ:IMMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.29+8.0%$2.39$1.28▼$7.85$232.96M1.151.38 million shs3.68 million shsDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsHOWLWerewolf Therapeutics$1.41+2.9%$1.28$0.60▼$4.18$62.65M0.64135,527 shs426,301 shsIMMPPrima BioMed$1.63+1.9%$1.70$1.32▼$2.72$234.86M1.7180,712 shs64,332 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-4.07%+2.42%-10.17%-15.87%-65.92%DBVTDBV Technologies+7.69%-0.40%-4.28%+7.80%+140.99%HOWLWerewolf Therapeutics+3.01%+5.38%+17.09%+11.38%-35.68%IMMPPrima BioMed-6.98%-2.44%-10.61%-13.51%-38.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.29+8.0%$2.39$1.28▼$7.85$232.96M1.151.38 million shs3.68 million shsDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsHOWLWerewolf Therapeutics$1.41+2.9%$1.28$0.60▼$4.18$62.65M0.64135,527 shs426,301 shsIMMPPrima BioMed$1.63+1.9%$1.70$1.32▼$2.72$234.86M1.7180,712 shs64,332 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-4.07%+2.42%-10.17%-15.87%-65.92%DBVTDBV Technologies+7.69%-0.40%-4.28%+7.80%+140.99%HOWLWerewolf Therapeutics+3.01%+5.38%+17.09%+11.38%-35.68%IMMPPrima BioMed-6.98%-2.44%-10.61%-13.51%-38.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.75Moderate Buy$12.50445.85% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7554.94% UpsideHOWLWerewolf Therapeutics 3.00Buy$8.00467.38% UpsideIMMPPrima BioMed 3.00Buy$7.00329.45% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, DBVT, IMMP, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025HOWLWerewolf TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/25/2025HOWLWerewolf TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.008/21/2025HOWLWerewolf TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.008/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/ADBVTDBV Technologies$4.15M62.85N/AN/A$1.42 per share6.70HOWLWerewolf Therapeutics$1.88M34.30N/AN/A$1.65 per share0.85IMMPPrima BioMed$6.69M35.76N/AN/A$0.63 per share2.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.64N/AN/AN/AN/A-111.87%-62.68%11/6/2025 (Estimated)IMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/ALatest HOWL, DBVT, IMMP, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/14/2025Q2 2025HOWLWerewolf Therapeutics-$0.50-$0.40+$0.10-$0.40$1.50 millionN/A7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67DBVTDBV TechnologiesN/A2.452.45HOWLWerewolf Therapeutics0.605.305.30IMMPPrima BioMedN/A11.69N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ADBVTDBV Technologies71.74%HOWLWerewolf Therapeutics64.84%IMMPPrima BioMed2.32%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%DBVTDBV Technologies1.44%HOWLWerewolf Therapeutics23.60%IMMPPrima BioMed3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million96.84 millionOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableHOWLWerewolf Therapeutics4045.73 million34.94 millionOptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionableHOWL, DBVT, IMMP, and ANNX HeadlinesRecent News About These CompaniesImmutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025September 8 at 8:00 AM | globenewswire.comImmutep Quarterly Activities Report Q4 FY25July 30, 2025 | globenewswire.comImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung CancerJuly 29, 2025 | globenewswire.comImmutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma TrialMay 28, 2025 | tipranks.comImmutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | finanznachrichten.deImmutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | globenewswire.comImmutep’s efti combination meets primary endpoint in Phase II soft tissue sarcoma trialMay 26, 2025 | sharecafe.com.auSImmutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma TrialMay 25, 2025 | tipranks.comImmutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 16, 2025 | manilatimes.netMImmutep reports promising lung cancer trial resultsMay 16, 2025 | investing.comImmutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15, 2025 | finance.yahoo.comIs Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comImmutep’s Efti Combination Shows Promising Results in Lung Cancer TrialMay 14, 2025 | tipranks.comImmutep Limited: Surging On Positive Head And Neck DataMay 8, 2025 | seekingalpha.comImmutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPSMay 5, 2025 | manilatimes.netMImmutep’s Efti Shows Promising Results in Head and Neck Cancer TrialMay 4, 2025 | tipranks.comImmutep Quarterly Activities Report Q3 FY25April 29, 2025 | finance.yahoo.comImmutep Limited Reports First Patient Dosed in TACTI-004 Phase III Lung Cancer Trial and Updates on Clinical ProgressApril 29, 2025 | quiverquant.comQImmutep Advances Cancer Trials with Promising DevelopmentsApril 28, 2025 | tipranks.comImmutep to Participate in Upcoming Investor ConferencesApril 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, DBVT, IMMP, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$2.29 +0.17 (+8.02%) Closing price 04:00 PM EasternExtended Trading$2.30 +0.01 (+0.39%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.DBV Technologies NASDAQ:DBVT$9.59 +0.19 (+1.97%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Werewolf Therapeutics NASDAQ:HOWL$1.41 +0.04 (+2.92%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.64%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Prima BioMed NASDAQ:IMMP$1.63 +0.03 (+1.88%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
